EDESA BIOTECH, INC. Share-based Payment Arrangement, Expense
EDESA BIOTECH, INC. (EDSA) reported Share-based Payment Arrangement, Expense of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- EDESA BIOTECH, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $500.00K, a 150.00% increase year-over-year.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $480.00K, a 585.71% increase year-over-year.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $400.00K, a 400.00% increase year-over-year.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $400.00K, a 300.00% increase year-over-year.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for fiscal 2025 was $700.00K, a 40.00% increase from fiscal 2024.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for fiscal 2024 was $500.00K, a 58.33% decline from fiscal 2023.
- EDESA BIOTECH, INC. share-based payment arrangement, expense for fiscal 2023 was $1.20M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-13 | $980.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.40M 10-Q · filed 2026-08-13 | $1.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $480.00K 10-Q · filed 2026-05-14 | $880.00K 10-Q · filed 2026-05-14 | $1.28M derived: sum of 3 quarters · filed 2026-05-14 | $1.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $400.00K 10-Q · filed 2026-02-13 | $800.00K derived: sum of 2 quarters · filed 2026-02-13 | $1.00M derived: sum of 3 quarters · filed 2026-08-13 | $1.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $600.00K derived: sum of 2 quarters · filed 2026-08-13 | $670.00K derived: sum of 3 quarters · filed 2026-08-13 | $700.00K 10-K · filed 2025-12-12 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-13 | $270.00K derived: sum of 2 quarters · filed 2026-08-13 | $300.00K 10-Q · filed 2026-08-13 | $450.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $70.00K 10-Q · filed 2026-05-14 | $150.00K 10-Q · filed 2026-05-14 | $250.00K derived: sum of 3 quarters · filed 2026-05-14 | $350.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $80.00K 10-Q · filed 2026-02-13 | $180.00K derived: sum of 2 quarters · filed 2026-02-13 | $280.00K derived: sum of 3 quarters · filed 2026-02-13 | |
| 2024-09-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $200.00K derived: sum of 2 quarters · filed 2025-12-12 | $500.00K 10-K · filed 2025-12-12 | |
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-08 | $400.00K 10-Q · filed 2025-08-08 | ||
| 2023-09-30 | $1.20M 10-K · filed 2024-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |